Literature DB >> 16224249

Muscle regeneration through myostatin inhibition.

Kathryn R Wagner1.   

Abstract

PURPOSE OF REVIEW: Myostatin is an endogenous, negative regulator of muscle growth. Selective inhibition of myostatin may have broad clinical utility by improving regeneration in diverse and burdensome muscle disorders. An understanding of this potential is relevant because inhibitors of myostatin have recently entered clinical trials. RECENT
FINDINGS: This article reviews the structure and function of myostatin, the effect of inhibiting myostatin in models of disease, and potential therapeutic approaches to blocking myostatin pharmacologically. The possibility that a myostatin inhibitor will promote muscle regeneration in human disease, as seen in animal models, is suggested by the observation that loss of myostatin results in muscle hypertrophy in a human subject.
SUMMARY: Multiple approaches to inhibiting myostatin are suggested by the recent elucidation of its signaling pathway. An inhibitor of myostatin may be the first drug specifically designed to enhance muscle growth and regeneration.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16224249     DOI: 10.1097/01.bor.0000184163.61558.ca

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  21 in total

1.  Administration of a soluble activin type IIB receptor promotes skeletal muscle growth independent of fiber type.

Authors:  Samuel M Cadena; Kathleen N Tomkinson; Travis E Monnell; Matthew S Spaits; Ravindra Kumar; Kathryn W Underwood; R Scott Pearsall; Jennifer L Lachey
Journal:  J Appl Physiol (1985)       Date:  2010-05-13

2.  Recombinant myostatin (GDF-8) propeptide enhances the repair and regeneration of both muscle and bone in a model of deep penetrant musculoskeletal injury.

Authors:  Mark W Hamrick; Phonepasong Arounleut; Ethan Kellum; Matthew Cain; David Immel; Li-Fang Liang
Journal:  J Trauma       Date:  2010-09

3.  Gene transfer demonstrates that muscle is not a primary target for non-cell-autonomous toxicity in familial amyotrophic lateral sclerosis.

Authors:  Timothy M Miller; Soo H Kim; Koji Yamanaka; Mark Hester; Priya Umapathi; Hannah Arnson; Liza Rizo; Jerry R Mendell; Fred H Gage; Don W Cleveland; Brian K Kaspar
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-12       Impact factor: 11.205

4.  Myostatin (GDF-8) inhibits chondrogenesis and chondrocyte proliferation in vitro by suppressing Sox-9 expression.

Authors:  Moataz Elkasrawy; Sadanand Fulzele; Matthew Bowser; Karl Wenger; Mark Hamrick
Journal:  Growth Factors       Date:  2011-07-15       Impact factor: 2.511

Review 5.  Approaching a new age in Duchenne muscular dystrophy treatment.

Authors:  Kathryn R Wagner
Journal:  Neurotherapeutics       Date:  2008-10       Impact factor: 7.620

6.  Resistance training induced increase in muscle fiber size in young and older men.

Authors:  A A Mero; J J Hulmi; H Salmijärvi; M Katajavuori; M Haverinen; J Holviala; T Ridanpää; K Häkkinen; V Kovanen; J P Ahtiainen; H Selänne
Journal:  Eur J Appl Physiol       Date:  2012-08-17       Impact factor: 3.078

7.  Immunolocalization of myostatin (GDF-8) following musculoskeletal injury and the effects of exogenous myostatin on muscle and bone healing.

Authors:  Moataz Elkasrawy; David Immel; Xuejun Wen; Xiaoyan Liu; Li-Fang Liang; Mark W Hamrick
Journal:  J Histochem Cytochem       Date:  2012-01       Impact factor: 2.479

8.  Knockdown of endogenous myostatin promotes sheep myoblast proliferation.

Authors:  Chenxi Liu; Wenrong Li; Xuemei Zhang; Ning Zhang; Sangang He; Juncheng Huang; Yubin Ge; Mingjun Liu
Journal:  In Vitro Cell Dev Biol Anim       Date:  2013-09-20       Impact factor: 2.416

9.  Myostatin directly regulates skeletal muscle fibrosis.

Authors:  Zhao Bo Li; Helen D Kollias; Kathryn R Wagner
Journal:  J Biol Chem       Date:  2008-05-03       Impact factor: 5.157

10.  Muscle hypertrophy driven by myostatin blockade does not require stem/precursor-cell activity.

Authors:  Helge Amthor; Anthony Otto; Adeline Vulin; Anne Rochat; Julie Dumonceaux; Luis Garcia; Etienne Mouisel; Christophe Hourdé; Raymond Macharia; Melanie Friedrichs; Frederic Relaix; Peter S Zammit; Antonios Matsakas; Ketan Patel; Terence Partridge
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-21       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.